Everyway Incontinence Stimulation System is intended to provide electrical stimulation and neuromuscular re-education for the purpose of rehabilitation of weak pelvic floor muscles for the treatment of stress, urge and mixed urinary incontinence in women and to maintain urinary continence in women.

Device Description

The Everyway Incontinence Stimulation System is a dual channel powered muscle stimulator intended to provide electrical stimulation and neuromuscular re-education for the purpose of rehabilitation of weak pelvic floor muscles for the treatment of stress, urge and mixed urinary incontinence in women and to maintain urinary continence in women.

The EV-805I stimulator is basically an Everyway's existing K071951-510(K) cleared model for power muscle stimulator. To make it delivery the same stimulation output as that of chosen predicate device, we made some change in software so as to generate muscle stimulation current that is discharged through the PR-02A, PR-04A, PR-14A Life-Care Vaginal Probe on the vaginal skin for the treatment of urinary incontinence.

The device is operated in such a way that turn on the intensity control knob and adjust the intended intensity or turn off the device during operation through the same control knob. While device is turned on for operation, the related LCD icons then illuminate for indicating the device is in operation condition. User then follow the instruction for use to get appropriate stimulation treatment for urinary incontinence.

With the combination of the main device parts as above mentioned , the device can be used as recommended in manual for the treatment of urinary incontinence for over-the-counter (OTC) use as that of the chosen 510(K) predicate device.

AI/ML Overview

The Everyway Incontinence Stimulation System is an electrical muscle stimulator intended for the rehabilitation of weak pelvic floor muscles to treat stress, urge, and mixed urinary incontinence in women and maintain urinary continence.

Here's an analysis of the acceptance criteria and the study performed, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance:

The document doesn't explicitly state "acceptance criteria" as a pass/fail threshold for a performance metric in the way it might for a diagnostic device (e.g., sensitivity of X, specificity of Y). Instead, the study's goal was to demonstrate substantial equivalence to a predicate device. This is primarily achieved through comparing technical characteristics and demonstrating comparable safety and effectiveness.

The table below outlines the comparison of key parameters between the proposed device and its predicate:

Feature	Predicate Device (Yarlap K141643)	Proposed Device (Everyway Incontinence Stimulation System K161349)	Comparison Outcome
Model Name	Yarlap	Everyway Incontinence Stimulation System	Different
510(K) No.	K141643	K161349	Different
Prescription or OTC	OTC	OTC	Same
FDA product code	KPI	KPI	Same
Indication for Use	Same as proposed device	The device is intended to provide electrical stimulation and neuromuscular re-education for the purpose of rehabilitation of weak pelvic floor muscles for the treatment of stress, urge and mixed urinary incontinence in women and to maintain urinary continence in women.	Same
Electrode Used	Incontinence probe; Electrode area: 6.4cm² X2	Incontinence probe; Electrode area: PR-02A: 7.65cm² X2, PR-03A: 7.87cm² X2, PR-04A: 6.25cm² X2, PR-14A: 9.05cm² X2	Different
Maximum Current (P1-P6)	80mA	75mA	Different
Other Output Parameters (Phase Duration, Rate, ON/OFF Time, Timer)	Largely identical for each program mode	Largely identical for each program mode (minor differences in P6's Rate, ON Time, OFF Time, Timer compared to predicate's P6, but overall consistent with other modes where predicate P6 is 80mA and 200us)	Largely Similar

Reported Device Performance:
The document states that a "Usability Study was conducted for the Everyway Incontinence Stimulation System to support the device design and labeling for over-the-counter use of the device." Specific performance metrics from this usability study (e.g., success rates, time to task completion, error rates) are not provided in this summary. The conclusion is that "verification and validation tests contained in this submission demonstrate that the difference in the submitted models could maintain the same safety and effectiveness as that of cleared device."

2. Sample Size Used for the Test Set and Data Provenance:

The document mentions a "Usability Study" but does not specify the sample size used for the test set. It also does not mention the country of origin of the data or whether the study was retrospective or prospective.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications:

The document mentions a "Usability Study" but does not describe the establishment of a "ground truth" in the context of expert review for a diagnostic or classification task, as the device is a therapeutic stimulation system. Therefore, no information is provided on the number or qualifications of experts for ground truth establishment.

4. Adjudication Method for the Test Set:

Given that the study described is a "Usability Study" for a therapeutic device and not a diagnostic efficacy study involving expert review for ground truth, an adjudication method for a test set (like 2+1 or 3+1) is not applicable and therefore not mentioned.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

A Multi-Reader Multi-Case (MRMC) comparative effectiveness study focusing on how human readers improve with AI vs. without AI assistance was not mentioned or performed. This type of study is typically relevant for diagnostic AI applications, not for an electrical stimulation system for incontinence.

6. Standalone (Algorithm Only) Performance:

The device is an electrical stimulation system, not an AI algorithm. Therefore, a standalone performance study in the context of an algorithm's performance without human intervention is not applicable and not reported.

7. Type of Ground Truth Used:

For the usability study, the "ground truth" would likely relate to objective measures of user interaction, user feedback, and successful operation of the device according to instructions. However, the document does not explicitly state the type of ground truth used for the usability study. It is not pathology, expert consensus on images, or long-term outcomes data as might be seen for other device types.

8. Sample Size for the Training Set:

The document describes a "Usability Study," not an AI model. Therefore, there is no training set in the context of machine learning, and thus no sample size is applicable or reported for such a set.

9. How the Ground Truth for the Training Set Was Established:

As there is no training set for an AI model mentioned in the context of this device, the question of how its ground truth was established is not applicable.

Summary

{0}------------------------------------------------

Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

July 7, 2017

Everyway Medical Instrument Co., Ltd. Robert Tu President and Operator Owner 3FL., No. 5, Lane 155, Section 3, Beishen Rd. Shenkeng Dist, New Taipei City, Taiwan 22203 R.O.C.

Re: K161349 Trade/Device Name: Everyway Incontinence Stimulation System Regulation Number: 21 CFR& 876.5320 Regulation Name: Nonimplanted electrical continence device Regulatory Class: II Product Code: KPI Dated: June 6, 2017 Received: June 7, 2017

Dear Robert Tu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Joyce M. Whang -S

for Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for EVERYWAY MEDICAL INSTRUMENTS CO., LTD. The logo consists of the word "EVERYWAY" in a stylized font, with horizontal lines above and below the word. The text "EVERYWAY MEDICAL INSTRUMENTS CO.,LTD." is written in a simple, sans-serif font to the right of the stylized logo.

3F1., No. 5, Lane 155, Sec. 3,Beishen Rd, Shenkeng Dist, New Taipei City, Taiwan,

Indications For Use

510(k) Number (if known): K161349

Device Name: Everyway Incontinence Stimulation System

Indications For Use:

Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of _ 1

{3}------------------------------------------------

3Fl., No. 5, Lane 155, Sec. 3,Beishen Rd, Shenkeng Dist, New Taipei City, Taiwan,

510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is being prepared in accordance with the requirements of SMDA 1990 and 21 CFR 807.92 at July 06, 2017.

The assigned 510(k) number is: K161349 .

1. Submitter's Identifications: Establishment: EVERYWAY MEDICAL INSTRUMENTS CO., LTD. Address: 3Fl., No. 5, Lane 155, Sec. 3, Beishen Rd., Shenkeng Dist, New Taipei City 222, Taiwan Registration Number: 9616877 Operations: Manufacturer
  Owner/Operator: EVERYWAY MEDICAL INSTRUMENTS CO., LTD. Address : 3FI., No. 5, Lane 155, Sec. 3, Beishen Rd., Shenkeng Dist, New Taipei City 222, Taiwan Contact Person: Robert Tu Phone : 886-2-2662-0038 Fax No: 886-2-2664-5566 e-mail : robert@everyway-medical.com
1. Name of the Device: Everyway Incontinence Stimulation System
1. Information of the 510(k) Cleared Device (Predicate Device): K141643: Yarlap Nonimplanted electrical continence device. K122194: Life-Care Vaginal Probe models PR-02A, PR-03A, PR-04A, PR-14A (for reference) K071951:Everyway Comfy EMS/Model EV-805(for reference)

4. Classification Information:

Trade/Device Name: Everyway Incontinence Stimulation System Regulation Number: 21 CFR Part 876.5320 Regulation Name: Stimulator, Electrical, Non-implantable, For Incontinence. Regulatory Class: II Product Code: KPI

5. Device Description:

{4}------------------------------------------------

3F1., No. 5, Lane 155, Sec. 3,Beishen Rd, Shenkeng Dist, New Taipei City, Taiwan,

6. Intended Use:

The Everyway Incontinence Stimulation System is intended to provide electrical stimulation and neuromuscular re-education for the purpose of rehabilitation of weak pelvic floor muscles for the treatment of stress, urge and mixed urinary incontinence in women and to maintain urinary continence in women.

7. Comparison to the 510(k) Cleared Device (Predicate Device):

The main reason for choosing these two predicate 510(K) clear model are because that all of them bear the same intended use as well as almost the same accessories. For the comparison concerning the device features, please see the following comparison table:

Features	510(K) Proposed Model	New Model
Model Name	YarlapNonimplanted electrical continencedevice	Everyway Incontinence StimulationSystem
510(K) No.	K141643	K161349
Prescription orOTC	OTC	OTC
FDA productcode	KPI	KPI
Indication forUse	The device is intended to provideelectrical stimulation andneuromuscular re-education for thepurpose of rehabilitation of weakpelvic floor muscles for the treatmentof stress, urge and mixed urinaryincontinence in women and tomaintain urinary continence inwomen.	The Everyway IncontinenceStimulation System is intended toprovide electrical stimulation andneuromuscular re-education for thepurpose of rehabilitation of weakpelvic floor muscles for the treatmentof stress, urge and mixed urinaryincontinence in women and tomaintain urinary continence inwomen.
Electrode Used	Incontinence probePC Electrode area: $6.4cm²$ X2	Incontinence probeElectrode area:PR-02A: $7.65cm²$ X2PR-03A: $7.87cm²$ X2PR-04A: $6.25cm²$ X2PR-14A: $9.05cm²$ X2

{5}------------------------------------------------

3F1., No. 5, Lane 155, Sec. 3,Beishen Rd, Shenkeng Dist, New Taipei City, Taiwan,

In addition to the significant comparison feature, we also provided the comparison for the output characteristics as the following table :

For the operation mode, both predicate and new device provided the following six program modes:

New Device (EV-805I)
Program	Max.	Phase Duration	Rate	ON Time	OFF Time	Timer
P1	75mA	200us	12Hz	5 sec	5 sec.	15 min
P2	75mA	250us	20Hz	8 sec.	8 sec.	20 min
P3	75mA	200us	12Hz	5 sec.	10 sec.	15 min
P4	75mA	200us	10Hz	6 sec.	12 sec.	20 min
P5	75mA	250us	12Hz	5 sec.	15 sec.	15 min
P6	75mA	200us	35Hz	6 sec.	18 sec.	20 min
K141643 YARLAP
Program	Max.	Phase Duration	Rate	ON Time	OFF Time	Timer
P1	80mA	200us	12Hz	5 sec	5 sec.	15 min.
P2	80mA	250us	20Hz	8 sec.	8 sec.	20 min.
P3	80mA	200us	12Hz	5 sec.	10 sec.	15 min.
P4	80mA	200us	10Hz	6 sec.	12 sec.	20 min.
P5	80mA	250us	12Hz	5 sec.	15 sec.	15 min.

8. Discussion of Non-Clinical Tests Verification Activities Performed to Determine the Safety and Performance of the devices are as the followings:

35Hz

6 sec.

18 sec.

20 min.

80mA

200us

Compliance to applicable voluntary standards includes IEC 60601-2-10, as well as IEC 60601-1. IEC60601-1-11 and IEC 60601-1-2 requirement. In addition to the compliance of voluntary standards, the software verification has been carried out according to the FDA software guidance.

Discussion: The Compliance to applicable voluntary standards as above mentioned indicates that the new device in this submission used the same standards as that of predicate device. Therefore; we consider that the compliance of standards included in our submission is adequate for the determination of substantial equivalence.

9. Discussion of Clinical Test Validation Activities Performed to Determine the Effectiveness of Device are as the followings:

The Usability Study was conducted for the Everyway Incontinence Stimulation System to support the device design and labeling for over-the-counter use of the device.

{6}------------------------------------------------

3Fl., No. 5, Lane 155, Sec. 3,Beishen Rd, Shenkeng Dist, New Taipei City, Taiwan,

10. Summary for the technology comparison.

Basically the Everyway Incontinence Stimulation System has the similar technological characteristics with the predicate device in the product design, material, energy source type, main program mode and the main output waveform...etc. There exists some difference in the detailed output parameters (mainly in the output intensity and electrode sizes). Through the detailed calculation comparison of stimulation output energy for each operation mode(in particular the output current density and power density), we found the output level in each operation mode for our Everyway Incontinence Stimulation System and predicate device are very close and within the acceptable range. So we believe the difference in detailed output parameters does not affect the determination of substantial equivalence.

11. Conclusions

The Everyway Incontinence Stimulation System has the same intended use and the similar technological characteristics as the cleared devices. Moreover, verification and validation tests contained in this submission demonstrate that the difference in the submitted models could maintain the same safety and effectiveness as that of cleared device.

In the other words, those engineering difference do not: (1) affect the intended use or (2) alter the fundamental scientific technology of the device.

Regulation Number and Section

§ 876.5320 Nonimplanted electrical continence device.

(a)
Identification. A nonimplanted electrical continence device is a device that consists of a pair of electrodes on a plug or a pessary that are connected by an electrical cable to a battery-powered pulse source. The plug or pessary is inserted into the rectum or into the vagina and used to stimulate the muscles of the pelvic floor to maintain urinary or fecal continence. When necessary, the plug or pessary may be removed by the user. This device excludes an AC-powered nonimplanted electrical continence device and the powered vaginal muscle stimulator for therapeutic use (§ 884.5940).(b)
Classification. Class II (performance standards).